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Background: Lactobacillus species are used as bacterial vectors to deliver functional peptides to the intestine
because they are delivered live to the intestine, colonize the mucosal surface, and continue to produce the desired
protein. Previously, we generated a recombinant Lactobacillus casei secreting the cholera toxin B subunit (CTB),
which can translocate into intestinal epithelial cells (IECs) through GM1 ganglioside. Recombinant fusion proteins of
CTB with functional peptides have been used as carriers for the delivery of these peptides to IECs because of the
high cell permeation capacity of recombinant CTB (rCTB). However, there have been no reports of rCTB fused
with peptides expressed or secreted by Lactobacillus species. In this study, we constructed L. casei secreting a
recombinant fusion protein of CTB with YVAD (rCTB–YVAD). YVAD is a tetrapeptide (tyrosine–valine–alanine–aspartic
acid) that specifically inhibits caspase-1, which catalyzes the production of interleukin (IL)-1β, an inflammatory
cytokine, from its inactive precursor. Here, we examined whether rCTB–YVAD secreted by L. casei binds to GM1
ganglioside and inhibits caspase-1 activation in Caco-2 cells used as a model of IECs.
Results: We constructed the rCTB–YVAD secretion vector pSCTB–YVAD by modifying the rCTB secretion vector
pSCTB. L. casei secreting rCTB–YVAD was generated by transformation with pSCTB–YVAD. Both the culture
supernatant of pSCTB–YVAD-transformed L. casei and purified rCTB–YVAD bound to GM1 ganglioside, as did
the culture supernatant of pSCTB-transformed L. casei and purified rCTB. Interestingly, although both purified
rCTB–YVAD and rCTB translocated into Caco-2 cells, regardless of lipopolysaccharide (LPS), only purified rCTB–YVAD
but not rCTB inhibited LPS-induced caspase-1 activation and subsequent IL-1β secretion in Caco-2 cells, without
affecting cell viability.
Conclusions: The rCTB protein fused to a functional peptide secreted by L. casei can bind to GM1 ganglioside,
like rCTB, and recombinant YVAD secreted by L. casei may exert anti-inflammatory effects in the intestine.
Therefore, rCTB secreted by L. casei has potential utility as a vector for the delivery of YVAD to IECs.
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Lactic acid bacteria (LAB) are not pathogenic and their
classification is “generally recognized as safe”. Over the
past several decades, LAB have been used in foods and
medicines because they confer beneficial effects on the
health of the host. Moreover, after their administration,
LAB are delivered live to the intestine, colonizing the
mucosal surface and exerting various effects [1]. There-
fore, LAB that produce heterologous proteins have been
used as bacterial vectors for the delivery of functional
proteins to the intestine. Many studies using recombin-
ant DNA technology have used Lactobacillus species,
which are present in large numbers in the human gut
and are resistant to gastric and bile acids [2]. These live
recombinant lactobacilli colonize the intestinal mucosal
surface and produce the desired protein [3]. Although
Escherichia coli has generally been used for the produc-
tion of heterologous proteins, coliform lipopolysacchar-
ide (LPS) contamination always poses a problem. In
contrast to E. coli, Lactobacillus species are gram-positive
bacteria and consequently do not contain LPS. Therefore,
we selected Lactobacillus species for the secretion of func-
tional heterologous proteins.
Cholera toxin (CT) is an enterotoxin produced by
Vibrio cholerae, which is composed of a toxic A subunit
(CTA) and nontoxic B subunit (CTB). CT gains entry to
intestinal epithelial cells (IECs) when CTB binds to GM1
ganglioside, a cell-surface receptor present on mammalian
cells. CTB alone can translocate into IECs through the
GM1 ganglioside without toxicity [4]. Many groups have
reported that recombinant CTB (rCTB) expressed in
various bacteria, yeasts, and plants also binds to GM1
ganglioside. Previously, we constructed a recombinant
Lactobacillus casei that secretes CTB, and showed that
the rCTB secreted by L. casei has GM1-ganglioside-
binding activity similar to that of CT from V. cholerae [5].
Recombinant fusion proteins of CTB with functional
proteins and peptides, such as vaccine antigens [6] and
the insulin B chain peptide [7], have been used as carriers
to deliver these proteins and peptides to IECs, because
they also bind to GM1 ganglioside. However, it has not
been determined whether recombinant fusion proteins of
CTB with functional proteins or peptides expressed by
Lactobacillus species bind GM1 ganglioside and translo-
cate into IECs.
The synthetic tetrapeptide composed of tyrosine, valine,
alanine, and aspartic acid (YVAD) is a specific inhibitor of
caspase-1 [8]. Caspase-1 catalyzes the production of inter-
leukin (IL)-1β, an inflammatory cytokine, from its pre-
cursor (pro-IL-1β), and its overexpression in and secretion
from IECs exacerbates intestinal inflammation [9,10].
Caspase-1 is also produced as an inactive precursor,
pro-caspase-1, which is activated by inflammatory
stimuli, such as LPS and mature caspase-1 itself [11,12].Therefore, YVAD has anti-inflammatory properties, acting
as a decoy substrate for caspase-1 instead of pro-IL-1β
and pro-caspase-1. However, recombinant bacteria ex-
pressing or secreting YVAD have not been reported
because it is difficult to express and secrete recom-
binant low-molecular-weight peptides in bacteria. Further-
more, for YVAD to inhibit caspase-1 activation and
subsequent IL-1β secretion, it must be translocated into
IECs. However, the cell permeation capacity of YVAD is
low because of its strong polarity [13]. Here, we investi-
gated whether fusing rCTB to YVAD would allow the
secretion of recombinant YVAD from L. casei and facili-
tate the translocation of YVAD into IECs.
In this study, we constructed L. casei that secretes a
recombinant fusion protein of CTB with YVAD (rCTB–
YVAD) and confirmed that rCTB–YVAD secreted by
L. casei binds to GM1 ganglioside, translocates into
human epithelial colorectal adenocarcinoma Caco-2 cells
used as a model of IECs, and inhibits the activation
of caspase-1 and subsequent IL-1β secretion from
Caco-2 cells.
Results and discussion
Secretion of rCTB-YVAD by L. casei transformed with
pSCTB-YVAD
Recombinant fusion proteins of CTB with functional
peptides expressed in various bacteria [7,14], yeasts [6],
and plants [15] have been reported to bind GM1 gan-
glioside. However, there have been no reports of recom-
binant fusion proteins of CTB with functional peptides
expressed in Lactobacillus species. Liljegvist et al. re-
ported that the fusion of the serum albumin binding
region (BB, approximately 25 kDa) to the C-terminus
of CTB had no effect on the GM1-ganglioside-binding
activity of CTB, whereas this activity was abolished when
BB was fused to the N-terminus of CTB [16]. These ob-
servations demonstrate the importance of fusing the
functional peptide to the C-terminus of CTB to retain its
GM1-ganglioside-binding activity. In contrast, Dertzbaugh
and Cox reported that CTB can bind to nickel ions with-
out a His-tag because of a specific histidine residue within
its sequence [17]. However, we recently showed that the
purification of rCTB with a His-tag from the culture
supernatant of L. casei was 20 times more efficient than
the purification of rCTB without a His-tag [5]. The GM1-
ganglioside-binding activity of rCTB with a His-tag,
secreted by L. casei, was similar to those of rCTB without
a His-tag and native CT from V. cholerae [5]. Therefore,
to avoid any steric effects on the structure and GM1-
ganglioside-binding activity of rCTB secreted by L. casei,
we fused YVAD and the His-tag to the C-terminus of
CTB. The rCTB–YVAD secretion vector pSCTB–YVAD
includes the promoter region of the lactate dehydro-
genase (LDH) gene, the secretory signal sequence (SS)
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saminidase gene from L. casei, the CTB-coding sequence
from V. cholerae, the YVAD-coding sequence (tatgttgctgat;
this nucleotide sequence was determined by reference to
the codon usage of L. casei ATCC 334 and ATCC 393),
and the His-tag-coding sequence in the Lactobacillus–E.
coli shuttle vector pHIL253 [5] (Figure 1). Protein bands
of about 12–14 kDa were detected in the supernatant of
L. casei transformed with pSCTB–YVAD or pSCTB, when
immunoblotted with an antibody directed against CT
(Figure 2A). These results indicate that rCTB–YVAD and
rCTB, with predicted molecular weights of 13,231 and
12,783, respectively, were secreted by L. casei transformed
with pSCTB–YVAD and pSCTB, respectively. Further-
more, the supernatant of L. casei transformed with
pSCTB–YVAD showed strong binding activity to GM1
ganglioside compared with that of pHIL253 (0.78 ± 0.04
vs 0.06 ± 0.01 at OD405, respectively, P < 0.01; Figure 2B).
This GM1-ganglioside-binding activity was similar to that
of the supernatant of L. casei transformed with pSCTB
(0.61 ± 0.08 at OD405). These observations indicate that
rCTB–YVAD secreted by L. casei transformed with
pSCTB–YVAD has binding activity for GM1 ganglioside
similar to that of rCTB secreted by L. casei transformed
with pSCTB.Figure 1 Construction of rCTB–YVAD secretion vector pSCTB–YVAD. p
acetylglucosaminidase gene, the CTB–YVAD-coding sequence, His-tag-codi
the Lactobacillus–E. coli shuttle vector pHIL253. The nucleotide and aminoPurification of rCTB–YVAD secreted by pSCTB–YVAD-
transformed L. casei
To analyze the inhibitory effect of rCTB–YVAD secreted
by L. casei transformed with pSCTB–YVAD, it was ne-
cessary to coincubate Caco-2 cells with L. casei secreting
rCTB–YVAD. However, wild-type L. casei and L. casei
transformed with pHIL253, pSCTB–YVAD, or pSCTB
do not grow in minimum essential medium (MEM),
which is used to culture Caco-2 cells, but grow in MRS/K
(see Additional file 1: Figure S1A). Furthermore, neither
rCTB–YVAD nor rCTB was detected in the supernatant
of L. casei transformed with pSCTB–YVAD or pSCTB,
respectively, when grown in MEM, but both were detected
when the transformants were grown in MRS/K (see
Additional file 1: Figure S1B). Therefore, to analyze the in-
hibitory effect of rCTB–YVAD on LPS-induced caspase-1
activation and subsequent IL-1β secretion, we purified
rCTB–YVAD from the culture supernatant of L. casei
transformed with pSCTB–YVAD using its His-tag and a
nickel-bound affinity resin. The purified rCTB–YVAD
migrated as a single band on SDS-PAGE when visualized
with Coomassie Brilliant Blue (CBB) staining (Figure 3A).
Furthermore, purified rCTB–YVAD was detected by
immunoblotting with an antibody directed against CT
(Figure 3B) and bound more strongly to GM1 gangliosideSCTB–YVAD includes the promoter of the LDH gene, SS of the β-N-
ng sequence, and the Term of the β-N-acetylglucosaminidase gene in
acid sequences around the CTB/YVAD fusion site are shown.
Figure 2 Secretion and GM1-ganglioside-binding activity of rCTB–YVAD. Wild-type L. casei and L. casei transformed with pHIL253, pSCTB–
YVAD, or pSCTB were grown at 30°C. The culture supernatants were collected and concentrated 10-fold. Immunoblotting with an antibody directed
against CT was performed to analyze the secretion of rCTB–YVAD or rCTB into the supernatant. Data are representative of three separate experiments
(A). The GM1-ganglioside-binding activity in the supernatant was analyzed with GM1-ELISA. Data represent the means ± SEM of three separate
experiments performed in triplicate (B). **P < 0.01 compared with pHIL253.
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ively, P < 0.01; Figure 3C), similar to the supernatant of L.
casei transformed with pSCTB–YVAD (Figure 2B). The
GM1-ganglioside-binding activity of rCTB–YVAD was
similar to that of rCTB (0.56 ± 0.06 at OD405; Figure 3C).
Purified rCTB–YVAD and rCTB were used in further
experiments. About 1 mg of rCTB–YVAD protein was ob-
tained from one liter of culture supernatant from L. casei
transformed with pSCTB–YVAD. This purification effi-
ciency was similar to that for rCTB purified from the cul-
ture supernatant of pSCTB-transformed L. casei.
Viability of Caco-2 cells after rCTB–YVAD and rCTB treatment
There were no significant differences in the viability of
Caco-2 cells treated with PBS, rCTB-YVAD, or rCTB inFigure 3 Purification of rCTB–YVAD from the culture supernatant of L
using its His-tag with a nickel-bound affinity resin. Purification was confirm
with an antibody directed against CT (B). Data are representative of three s
rCTB–YVAD and rCTB were analyzed by GM1-ELISA. Data represent the me
**P < 0.01 compared with PBS.the presence of LPS (Figure 4). Therefore, rCTB–YVAD
and rCTB had no effect on Caco-2 cell viability in the
presence of LPS. Consequently, rCTB–YVAD and rCTB
were used at concentrations of 50 μM in subsequent
experiments.
Translocation of rCTB-YVAD and rCTB into Caco-2 cells
The translocation of rCTB–YVAD is a prerequisite
for the inhibition of LPS-induced caspase-1 activation
and subsequent IL-1β secretion. Therefore, we exam-
ined whether rCTB–YVAD translocates into Caco-2
cells. rCTB–YVAD was detected within Caco-2 cells
in the absence or presence of LPS (Figure 5). Simi-
larly, rCTB was detected within Caco-2 cells. These
results indicate that both rCTB–YVAD and rCTB are. casei transformed with pSCTB–YVAD. rCTB–YVAD was purified
ed by SDS-PAGE followed by CBB staining (A) and immunoblotting
eparate experiments. The GM1-ganglioside-binding activities of purified
ans ± SEM of three separate experiments performed in triplicate (C).
Figure 4 Viability of Caco-2 cells treated with rCTB–YVAD or
rCTB. Caco-2 cells were treated with three concentrations of rCTB–
YVAD or rCTB (10, 20, or 50 μM) for 48 h in the presence of 10 μg/ml
LPS. Caco-2 cell viability was measured with the WST-1 method and by
comparing the absorbance of untreated control cells with that of PBS-,
rCTB–YVAD-, and rCTB-treated cells. Data represent the means ± SEM
of three separate experiments performed in triplicate.
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treatment.
The cell permeation of functional peptides, such as
vaccine antigens and the insulin B chain peptide, is
increased by their fusion with CTB [6,7], because CTB
translocates easily into IECs by binding to GM1 ganglio-
side [4]. For YVAD to inhibit caspase-1 activation and
subsequent IL-1β secretion, it is necessary for YVAD to
translocate into Caco-2 cells. Our results suggest that
the fusion of CTB to YVAD contributed to the trans-
location of YVAD into Caco-2 cells. The translocation of
rCTB–YVAD into the cells, regardless of the presence
or absence of LPS, suggests that rCTB–YVAD translo-
cates into Caco-2 cells through GM1 ganglioside, whichFigure 5 Translocation of rCTB–YVAD or rCTB into Caco-2 cells. Caco-
absence or presence of 10 μg/ml LPS. The translocation of rCTB–YVAD or r
antibody directed against CT. β-actin was used as the internal control. Datais constantly expressed, regardless of the inflammatory
status.
Inhibitory effect of rCTB–YVAD on LPS-induced caspase-1
activation and subsequent IL-1β secretion in Caco-2 cells
The level of caspase-1 activity was significantly increased
in the lysate of LPS-treated Caco-2 cells compared with
that in the untreated control cells (P < 0.01). rCTB–
YVAD significantly inhibited LPS-induced caspase-1 acti-
vation compared with that in cells treated with LPS + PBS
(0.24 ± 0.01 vs 0.41 ± 0.03 at OD405, respectively, P < 0.01;
Figure 6A). This observation suggests that rCTB-YVAD
acts as a decoy substrate for caspase-1. The level of IL-1β
secretion increased in Caco-2 cells after LPS treatment
compared with that in the untreated controls (P < 0.01).
Treatment with rCTB–YVAD significantly reduced LPS-
induced IL-1β secretion compared with that in cells
treated with LPS + PBS (28.5 ± 3.6 vs 86.5 ± 4.7 pg/ml,
respectively, P < 0.01; Figure 6B). In contrast, treatment
with rCTB had no significant effect on LPS-induced
caspase-1 activation (0.42 ± 0.02 at OD405) or IL-1β secre-
tion (73.3 ± 5.0 pg/ml) compared with those in cells
treated with LPS + PBS (Figure 6). These results indicate
that rCTB had no effect on caspase-1 activation or subse-
quent IL-1β secretion, and that the inhibitory effect of
YVAD on capase-1 was not abolished by the fusion of
YVAD to CTB.
The expression and secretion of YVAD by bacteria
have been limited by its low molecular weight. Therefore,
we constructed recombinant L. casei secreting YVAD as a
fusion protein with CTB and showed that YVAD secreted
by L. casei inhibits caspase-1 activation and subsequent
IL-1β secretion. The results of this study indicate that
YVAD secreted by bacteria exerts an anti-inflammatory
effect. Meng et al. also reported that recombinant green2 cells were treated with 50 μM rCTB–YVAD or rCTB for 6 h in the
CTB into Caco-2 cells was detected with immunoblotting using an
are representative of three separate experiments.
Figure 6 Inhibitory effects of rCTB–YVAD on LPS-induced caspase-1 activation and IL-1β secretion in Caco-2 cells. Caco-2 cells were
treated with 10 μg/ml LPS for 12 h. The cell lysates were incubated at 30°C for 2 h in the absence or presence of 50 μM rCTB-YVAD or rCTB.
Caspase-1 activity was determined with a colorimetric assay (A). Caco-2 cells were treated with 50 μM rCTB–YVAD or rCTB in the presence of
10 μg/ml LPS. The concentrations of IL-1β in the supernatant were determined with an ELISA (B). Data are the means ± SEM of three separate
experiments performed in triplicate. ##P < 0.01 compared with the control, **P < 0.01 compared with LPS + PBS treatment.
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expressed in silkworms emitted green fluorescence similar
to that emitted by recombinant GFP alone [18]. That
report and the results of the present study suggest that the
effects of functional peptides or proteins are not abolished
by their fusion to the C-terminus of CTB.
Conclusions
We constructed an L. casei that secretes a recombinant
CTB protein fused to YVAD. Although rCTB–YVAD
bound GM1 ganglioside and translocated into Caco-2
cells, like rCTB, rCTB–YVAD but not rCTB inhibited
LPS-induced caspase-1 activation and subsequent IL-1β
secretion without affecting cell viability. These results in-
dicate not only that a recombinant fusion protein of CTB
with a functional peptide secreted by L. casei has GM1-
ganglioside-binding activity, but also that recombinant
YVAD secreted by L. casei exerts an anti-inflammatory ef-
fect. The results of this study suggest that rCTB secreted
by L. casei has potential utility as a system for the delivery
of YVAD into IECs. However, we were unable to examine
the anti-inflammatory effects of rCTB–YVAD-secreting L.
casei in this study because L. casei could not grow or
secrete rCTB–YVAD in MEM. We confirmed that it is
difficult to completely mimic the intestinal environment in
in vitro experiments. Therefore, further studies, such as an
in vivo study of the ingestion of rCTB–YVAD secreting L.
casei, are required to examine the effects of rCTB–YVAD-
secreting L. casei. If successful, such a study would confirm
that rCTB-secreting L. casei has potential utility as a deliv-
ery system for functional peptides into the intestine.
Methods
Bacterial strains and culture conditions
The strains used in this study were L. casei ATCC 27092
and E. coli DH5α. L. casei was grown at 37°C in MRSbroth to produce the recombinant strain or at 30°C in
MRS/K (MRS with 0.2 M potassium phosphate buffer)
to produce the cell culture supernatant [5]. Erythro-
mycin (5 μg/ml) was added to MRS or MRS/K to select
the recombinant strain. E. coli was grown at 37°C in LB
medium with or without ampicillin (100 μg/ml).
Construction of the rCTB–YVAD secretion vector
PCR was performed using the plasmid pSCTB [5] as the
template DNA, KOD-Plus- DNA polymerase (Toyobo,
Osaka, Japan), and primers containing the YVAD-coding
sequence fused to the C-terminus of the CTB gene:
sense, 5′-caccaccaccaccaccactaaaggccttc-3′; anti-sense,
5′-atcagcaacataatttgccatactaattgc-3′. Initial denaturation
was at 94°C for 2 min, followed by 30 cycles of denatur-
ation at 94°C for 15 sec, annealing at 50°C for 30 sec, and
extension at 68°C for 7 min. The DNA fragment of about
6,600 bp was separated by agarose gel electrophoresis and
extracted from the gel with the QIAquick Gel Extraction
Kit (Qiagen, Valencia, CA). The extracted DNA was
phosphorylated at the 5′ end with T4 polynucleotide
kinase (TaKaRa Bio, Shiga, Japan) and self-ligated with T4
DNA ligase (TaKaRa Bio). The rCTB–YVAD secretion
vector pSCTB–YVAD was confirmed by sequencing,
and then introduced into L. casei by electroporation, as
described previously [5].
Secretion of rCTB–YVAD by L. casei
Overnight cultures of L. casei transformed with pSCTB–
YVAD or pSCTB were inoculated into MRS/K medium
to an optical density at 600 nm (OD600) of 0.05, and the
cells were grown at 30°C until they reached an OD600 of
2.0. The culture supernatants were collected by centrifu-
gation (7,000 × g, 5 min, 4°C) and concentrated 10-fold
with Amicon Ultra Centrifugal Filter Units (10 kDa;
Merck Millipore, Tokyo, Japan). The secretion and
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YVAD and rCTB in the concentrated supernatant were
confirmed with immunoblotting using an antibody di-
rected against CT or a GM1 enzyme-linked immuno-
sorbent assay (GM1-ELISA), respectively.
Immunoblotting
The concentrated supernatants of L. casei (20 μl/lane),
rCTB–YVAD (100 ng/lane), and cellular protein extracts
of Caco-2 cells (50 μg/lane) were subjected to immuno-
blotting analysis. They were separated with SDS-PAGE
(10–18%) and transferred to polyvinylidene difluoride
membranes (GE Healthcare, Buckinghamshire, UK). Anti-
bodies directed against CT (Sigma-Aldrich, St. Louis,
MO) and β-actin (Cell Signaling Technology, Boston,
MA) were used as the primary antibodies. Alkaline phos-
phatase (AP)-labeled anti-rabbit IgG antibody (Cell Signal-
ing Technology) was used as the secondary antibody, and
binding was detected with a chemiluminescent substrate
of AP (CDP-Star Reagent; Biolabs, Beverly, MA).
GM1-ELISA
A GM1-ELISA was performed to determine specific
GM1-ganglioside-binding activities. Briefly, 96-well mi-
crotiter plates (Sumitomo Bakelite Co., Ltd., Tokyo,
Japan) were coated with 5 μg/ml monosialoganglioside
GM1 (Sigma-Aldrich) diluted in bicarbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3, pH 9.6), and incu-
bated overnight at 4°C. After incubation, the plates were
washed three times with PBS supplemented with 0.05%
Tween-20 (PBS-T), and then blocked with PBS contain-
ing 1% bovine serum albumin (Nacalai Tesque, Kyoto,
Japan) at 37°C for 2 h. After the plates were washed, the
concentrated supernatant of L. casei (100 μl/well), rCTB–
YVAD (50 ng/well), or rCTB (50 ng/well) was applied to
the wells and incubated at 37°C for 2 h. The plates were
incubated at 37°C for 2 h with antibody directed against
CT and AP-labeled anti-rabbit IgG antibody used as the
primary and secondary antibodies, respectively. The plates
were incubated with AP substrate (Sigma-Aldrich) at
37°C for 20 min, and the OD405 was then measured
with a microplate reader (ImmunoMini Nj-2300; Nunc,
Rochester, NY).
Purification of rCTB–YVAD secreted by L. casei
rCTB–YVAD from the culture supernatant of L. casei
transformed with pSCTB–YVAD was purified using the
His-tag and an affinity resin containing bound nickel
ions. The culture supernatant of L. casei transformed
with pSCTB–YVAD was collected by centrifugation
(12,000 × g, 30 min, 4°C) after growth in MRS/K medium
at 30°C until the OD600 was 2.0. After the supernatant
was filtered at 0.22 μm, imidazole was added to a final
concentration of 20 mM, and the culture supernatant wasthen adjusted to pH 7.0. Nickel resin (Ni Sepharose High
Performance; GE Healthcare) was added to the culture
supernatant and then mixed gently overnight at 4°C. The
open column was filled with resin, and then washed with
wash buffer (10 mM sodium phosphate, 500 mM NaCl,
20 mM imidazole, pH 7.4). rCTB–YVAD bound with
nickel resin was eluted with elution buffer (10 mM so-
dium phosphate, 500 mM NaCl, 500 mM imidazole,
pH 7.4). The eluted rCTB–YVAD was concentrated and
the buffer replaced with PBS using Amicon Ultra Centri-
fugal Filter Units (10 kDa). The protein concentration of
rCTB–YVAD was determined with Coomassie Protein
Assay Reagent (Pierce, Perbio Science, Bonn, Germany).
The purity of rCTB–YVAD was confirmed with SDS-
PAGE on 17% polyacrylamide gel, followed by CBB stain-
ing and immunoblotting using an antibody directed
against CT. The GM1-ganglioside-binding activities of
purified rCTB–YVAD and rCTB were confirmed with
GM1-ELISA.
Caco-2 cell viability assay
Caco-2 cells were cultured as described previously [19].
Aliquots of 5 × 103 Caco-2 cells were plated in each well
of a 96-well plate (Nunc). The cells were treated with
three concentrations of rCTB–YVAD or rCTB (10, 20,
or 50 μM) in the presence of 10 μg/ml LPS from E. coli
O55:B5 (Sigma-Aldrich). After incubation for 48 h, 20 μl
of WST-1 Cell Proliferation Reagent (TaKaRa Bio) was
added to each well. After 2 h, the OD450 and OD630 were
measured with a microplate reader. Cell viability was
calculated as (OD450 – OD630 of treated cells/OD450 –
OD630 of untreated control cells) × 100%.
Detection of translocated rCTB–YVAD and rCTB in Caco-2
cells
Aliquots of 7 × 105 Caco-2 cells were plated in each well of
six-well plates (Nunc). Cells were treated with 50 μM
rCTB–YVAD or rCTB in the absence or presence of 10 μg/
ml LPS. After incubation for 6 h, cellular protein extracts
were prepared with PRO-PREP Protein Extraction Solution
(iNtRON Biotechnology, Kyungki-Do, South Korea), ac-
cording to the manufacturer’s protocol. The protein
concentrations of the cellular protein extracts were deter-
mined with Coomassie Protein Assay Reagent. Intracellular
rCTB–YVAD and rCTB were detected by immunoblotting
with an antibody directed against CT. Equal loading was
confirmed with an antibody directed against β-actin.
Inhibitory effect on caspase-1 activity
Caspase-1 activity was determined with a modification
of a previously described method [20,21]. Aliquots of
1 × 107 Caco-2 cells were plated in 90 mm plastic culture
dishes (Nunc) and treated with or without 10 μg/ml LPS
for 12 h. The cells were washed with PBS and
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1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, pH 7.4)
supplemented with 10 mM DTT and 1 mM phenyl-
methylsulfonyl fluoride. The cells were incubated at 4°C
for 15 min and disrupted by 20 passages through a 23G
needle. The lysates were then centrifuged at 12,000 × g
for 5 min at 4°C and the supernatants collected. The
protein concentrations of the lysates were determined
with Coomassie Protein Assay Reagent. Aliquots of
10 μg/μl lysate were incubated at 30°C for 2 h in the
absence or presence of 50 μM rCTB–YVAD or rCTB.
The caspase-1 activity in the 10-fold-diluted lysate was
determined with a Caspase 1 Assay Kit, Colorimetric
(Calbiochem, La Jolla, CA).
Measurement of IL-1β by ELISA
Aliquots of 7 × 105 Caco-2 cells were plated in each well
of six-well plates. The cells were treated with 50 μM
rCTB–YVAD and rCTB in the presence of 10 μg/ml
LPS for 48 h. The cell supernatants were centrifuged at
15,000 × g for 5 min at 4°C and stored at −80°C until
IL-1β analysis. The concentrations of IL-1β in the cell
supernatants were determined with a human IL-1β
ELISA Kit (R&D Systems, Abingdon, UK).
Statistical analyses
Data are presented as means ± SEM. Statistical ana-
lyses were performed with Origin Pro 8.1 (OriginLab,
Northampton, MA). Differences were analyzed with
one-way ANOVA followed by Tukey’s test. In all analyses,
P < 0.05 was deemed to indicate significance.
Additional file
Additional file 1: Figure S1. Culture of L. casei and its secretion of
rCTB–YVAD or rCTB in MRS/K or MEM. The data confirm that L. casei does
not grow or secrete rCTB–YVAD when cultured in MEM.
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